New insights into HER2-low breast cancer brain metastasis: A retrospective analysis

作者：Hangcheng Xu, Yan Wang, Li Li, Yiqun Han, Yun Wu, Qiang Sa, Binghe Xu, Jiayu Wang · 发表于：The Breast · 年份：2024 · DOI：10.1016/j.breast.2023.103669 · 被引用次数：4 · 研究领域：Brain Metastases and Treatment、HER2/EGFR in Cancer Research、Lung Cancer Research Studies

BACKGROUND: A considerable number of patients with breast cancer will suffer from brain metastasis in the advanced setting. The HER2 status serves as a significant prognostic factor and the reference of applying treatment for patients with breast cancer brain metastasis (BCBM). METHODS: Between January 2010 and July 2021, patients with BCBM who had available HER2 status were identified. The patients with HER2 1+ in immunohistochemistry (IHC) or IHC 2+ and fluorescence in situ hybridization (FISH) negative were categorized as HER2-low. Comparisons were conducted between the HER2-low and HER2-zero population. The primary endpoint was overall survival (OS) after the diagnosis of BCBM. Survival outcomes were assessed using Kaplan-Meier curves with log-rank test and Cox proportional hazards model. RESULTS: In this study, we analyzed 71 patients with the HER2-low breast cancer subtype and 64 patients with the HER2-zero subtype. Despite the limited sample size, our findings revealed a significantly better OS for patients with HER2-low cancer compared to their HER2-zero counterparts (26 m vs 20 m, p = 0.0017). This trend was particularly notable in the HR-negative group (26 m vs 13 m, p = 0.0078), whereas no significant difference was observed among the HR-positive patients. Furthermore, Cox regression analysis revealed that the HER2-low status was an independent prognostic factor for better survival in the HR-negative patients (p = 0.046 in multivariate analysis). CONCLUSIONS: Patie...